Abstract:Background: α1-Antitrypsin (A1AT) deficiency predisposes patients to pulmonary disease due to inadequate protection against human neutrophil elastase released during inflammatory responses. A1AT deficiency is caused by homozygosity or compound heterozygosity for A1AT variants; individuals with A1AT deficiency most commonly have at least one Z variant allele (c.1096G > A (Glu366Lys)). Null variants that result in complete absence of A1AT in the plasma are much rarer. With one recent exception, all reported A1AT variants are characterized by a single pathogenic variant. Case: An 8 years old patient from Edmonton, Alberta, Canada, was investigated for A1AT deficiency. His A1AT phenotype was determined to be M (wild type)/Null by isoelectric focusing (IEF) but M/Z by targeted genotyping. Gene sequencing revealed two heterozygous variants: Z and Ile100Asn (c.299 T > A). The Ile100Asn substitution is predicted to disrupt the secondary structure of an α-helix in which it resides and the neighbouring tertiary structure, resulting in intracellular degradation of A1AT prior to hepatocyte secretion. Methods: Family testing was conducted to verify potential inheritance of an A1AT allele carrying the two mutations in cis, as this arrangement of the mutations would explain "Z" detection by genotyping but not by IEF. Molecular modeling was used to assess the effect of the variants on A1AT structure and stability. Discussion: Carrier status for a novel variant NullCanada with in cis mutations (c.[299 T > A;1096G > A], p.[(Ileu100Asn;Glu366Lys)]) was confirmed. A sibling was identified as having A1AT deficiency on the basis of compound heterozygosity for two alleles: NullCanada and the common Z allele. A separate pedigree from the Maritimes was subsequently recognized as carrying NullCanada. Conclusion: In cis mutations such as NullCanada may be more common than previously described due to failure to detect such mutations using historical testing methods. Combined approaches that include gene sequencing and segregation studies allow recognition of rare A1AT variants, including in cis mutations.

Case report of a novel alpha1-antitrypsin null variant in Türkiye: Q0RİZE

Rare variants in alpha 1 antitrypsin deficiency: a systematic literature review

A rare AAT variant presenting in a COPD patient: Q0 amersfoort mutation

Identification and characterisation of eight novel SERPINA1 Null mutations

Alpha-1 Antitrypsin Deficiency in a Young Never Smoker With Novel Pi*Null Homozygous Mutation: a Case Report

Rare SERPINA1 variants leading to severe Alpha-1 Antitrypsin Deficiency

NullCanada: A novel α1-antitrypsin allele with in cis variants Glu366Lys and Ile100Asn

Cleaning up alpha-1 antitrypsin deficiency related liver disease

Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil

Novel Transgenic Humanized Alpha-1 Antitrypsin Deficiency Mouse Model on Murine SERPINA1 Null Background

Quantification of circulating alpha-1-antitrypsin polymers associated with different SERPINA1 genotypes

Research progress ofα1-antitrypsin deficiency of mutant Z

Alpha-1 antitrypsin deficiency: A conformational disease associated with lung and liver manifestations

Characteristics of Patients With Alpha-1 Antitrypsin Deficiency From Rural Appalachia: A Retrospective Single-Center Study

Advances in Alpha-1-Antitrypsin Deficiency Liver Disease

Oxidation‐resistant and Thermostable Forms of Alpha‐1 Antitrypsin from Escherichia Coli Inclusion Bodies

Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential

S4447 Esophageal and Gastric Variceal Hemorrhage Lead to Discovery of Isolated Hepatic Decompensation Secondary to A1AT Deficiency

Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiency

Future Perspectives in the Diagnosis and Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency

Alpha-1 deficiency in severe asthma patients